Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3.

We previously discovered a novel missense mutation (Lys650Met) in the tyrosine kinase domain of the fibroblast growth factor receptor 3 (FGFR3) gene in four unrelated individuals with a condition we called "severe achondroplasia with developmental delay and acanthosis nigricans" (SADDAN) [Tavormina et al., 1999: Am. J. Hum. Genet. 64:722-731]. Here we present a more detailed clinical account of the SADDAN phenotype. The FGFR3 Lys650Met mutation results in severe disturbances in endochondral bone growth that approach and overlap those observed in thanatophoric dysplasia, type I. However, this mutation is most often compatible with survival into adulthood. Other unusual bone deformities, such as femoral bowing with reverse (i.e., posterior apex) tibial and fibular bowing and "ram's horn" bowing of the clavicle, are also seen in some patients. In addition to skeletal dysplasia, progressive acanthosis nigricans, and central nervous system structural anomalies, seizures and severe developmental delays are observed in surviving SADDAN patients. Despite its location within the same FGFR3 codon as the thanatophoric dysplasia type II mutation (Lys650Glu) and a similar effect on constitutive activation of the FGFR3 tyrosine kinase, the Lys650Met is not associated with cloverleaf skull or craniosynostosis.

[1]  I. Kaitila,et al.  A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.

[2]  R. Friesel,et al.  Ligand-independent Activation of Fibroblast Growth Factor Receptors by Point Mutations in the Extracellular, Transmembrane, and Kinase Domains* , 1996, The Journal of Biological Chemistry.

[3]  R. Pyeritz,et al.  Cervicomedullary compression in young patients with achondroplasia: value of comprehensive neurologic and respiratory evaluation. , 1987, The Journal of pediatrics.

[4]  D. Accili,et al.  Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance and acanthosis nigricans. , 1992, The Journal of investigative dermatology.

[5]  D. Ornitz,et al.  Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. , 1998, Development.

[6]  S. Werner,et al.  Targeted expression of a dominant‐negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. , 1993, The EMBO journal.

[7]  B. Angle,et al.  Molecularly proven hypochondroplasia with cloverleaf skull deformity: a novel association , 1998, Clinical genetics.

[8]  J. Annegers,et al.  Mortality in achondroplasia. , 1987, American journal of human genetics.

[9]  D. Ornitz,et al.  Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia , 1996, Nature Genetics.

[10]  E. Jabs.  Toward understanding the pathogenesis of craniosynostosis through clinical and molecular correlates , 1998, Clinical genetics.

[11]  Beta2-integrin antigen expression in different types of urticaria , 1992 .

[12]  R. Pauli,et al.  Long-term survival in typical thanatophoric dysplasia type 1. , 1997, American journal of medical genetics.

[13]  P. Leder,et al.  Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth , 1996, Cell.

[14]  B. Elewski,et al.  Introduction: International Summit on Cutaneous Antifungal Therapy* , 1994 .

[15]  D. Rimoin,et al.  Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.

[16]  F. Walsh,et al.  Activation of the FGF receptor underlies neurite outgrowth stimulated by L1, N-CAM, and N-cadherin , 1994, Neuron.

[17]  Arnold Munnich,et al.  Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.

[18]  J. Flier.  Metabolic importance of acanthosis nigricans. , 1985, Archives of dermatology.

[19]  S. Takashima,et al.  Neuropathological and Golgi study on a case of thanatophotoric dysplasia , 1985, Brain and Development.

[20]  R. Schwartz,et al.  Childhood acanthosis nigricans. , 1995, Cutis.

[21]  F. Walsh,et al.  A soluble chimeric form of the L1 glycoprotein stimulates neurite outgrowth , 1995, Neuron.

[22]  A. N. Meyer,et al.  Constitutive receptor activation by Crouzon syndrome mutations in fibroblast growth factor receptor (FGFR)2 and FGFR2/Neu chimeras. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Werner,et al.  Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. , 1993, Developmental biology.

[24]  W. Reardon,et al.  A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome , 1994, Nature Genetics.

[25]  J. Mulley,et al.  Deafness due to Pro250Arg mutation of FGFR3 , 1998, The Lancet.

[26]  A. Munnich,et al.  Fibroblast Growth Factor Receptor 3 Mutations Promote Apoptosis but Do Not Alter Chondrocyte Proliferation in Thanatophoric Dysplasia* , 1998, The Journal of Biological Chemistry.

[27]  D. Church,et al.  Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.

[28]  A. Munnich,et al.  Stop codon FGFR3 mutations in thanatophoric dwarfism type 1 , 1995, Nature Genetics.

[29]  E. Haan,et al.  A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. , 1997, American journal of human genetics.

[30]  D. Rimoin,et al.  Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. , 1998, American journal of medical genetics.

[31]  P. Cruz,et al.  Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. , 1992, The Journal of investigative dermatology.

[32]  D. Donoghue,et al.  A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. , 1999, American journal of human genetics.

[33]  I. M. Baybekov,et al.  Successful treatment of acanthosis nigricans with etretinate. , 1994, Journal of the American Academy of Dermatology.

[34]  D. Donoghue,et al.  Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II , 1996, Molecular and cellular biology.

[35]  E. Zackai,et al.  Identical mutations in three different fibroblast growth factor receptor genes in autosomal dominant craniosynostosis syndromes , 1996, Nature Genetics.

[36]  M. Bamshad,et al.  Fibroblast growth factor receptor 2 mutations in Beare–Stevenson cutis gyrata syndrome , 1996, Nature Genetics.

[37]  U. Roessmann,et al.  Neuropathological findings in thanatophoric dysplasia. , 1983, Archives of pathology & laboratory medicine.

[38]  S. Werner,et al.  Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. , 1992, Development.

[39]  Gary W. Harding,et al.  Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 , 1996, Nature Genetics.

[40]  Xin-Yuan Fu,et al.  Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism , 1997, Nature.

[41]  D. Donoghue,et al.  Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. , 1996, The EMBO journal.

[42]  I. Munro,et al.  Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans , 1995, Nature Genetics.

[43]  M J Banda,et al.  Large induction of keratinocyte growth factor expression in the dermis during wound healing. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[44]  I. MacDonald,et al.  Growth and development in thanatophoric dysplasia. , 1989, American journal of medical genetics.